Patients with hepatitis C can see the finish line – a cure could be a reality for as many as 99% of people prescribed the new medication Harvoni®. Yet, so many untreated patients remain who want to cross that finish line. How come? The answer lies in delays and denials from the insurance companies of hepatitis C patients.
This is what we’ve seen with some BioPlus Specialty Pharmacy patients: insurance companies create hold ups or outright claim denials for patients prescribed Harvoni by their physicians. Other pharmacies have reported similar problems – so much so that these insurance “delay tactics” have been the reason that actual sales of hepatitis C medications lag behind forecasted sales in the United States market.
Some insurers cite the American Association for the Study of Liver Diseases (AASLD) treatment guidelines in their refusal to treat patients who don’t yet have cirrhosis or stage 3 fibrosis. This misuse of the guidelines even led the AASLD to release a statement clarifying that nearly all hepatitis C patients can benefit from treatment while some patients require urgent initiation (those with advanced disease).
Of course, we’ll continue to advocate for our BioPlus patients and with persistence get them the treatment that means a cure from this life-threatening disease. Let’s see all hepatitis C patients make it across that finish line.